Cytoki Pharma ApS: Financial statements 2024
CVR: 40594132
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Cytoki Pharma ApS (CVR 40594132) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -39,132,575 and a net result of DKK -39,261,697 compared with DKK -64,519,466 the year before. Equity in the 2024 report amounted to DKK 57,273,555. The solvency ratio was 91.1%. The company had 4 employees in the financial year.
- Gross Profit
- DKK -39,132,575
- Profit/Loss
- DKK -39,261,697
- Equity
- DKK 57,273,555
- Total Assets
- DKK 62,886,049
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -39.1 mio. | -39.3 mio. | 57.3 mio. | 4 |
| 2023 | - | -61.5 mio. | -64.5 mio. | 66.7 mio. | 5 |
| 2022 | - | -98.8 mio. | -98.4 mio. | 51.2 mio. | 4 |
| 2021 | - | -32 mio. | -29.8 mio. | 106.8 mio. | 3 |
| 2020 | - | -6 mio. | -6.8 mio. | -9.8 mio. | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of May 8, 2024, is registered as an owner of Cytoki Pharma ApS with an ownership share of 15%.
As of May 8, 2024, is registered as an owner of Cytoki Pharma ApS with an ownership share of 20%.
As of May 8, 2024, is registered as an owner of Cytoki Pharma ApS with an ownership share of 5%.
As of April 1, 2024, Klaus Andreas Dugi has joined the board of directors of Cytoki Pharma ApS.
As of March 31, 2024, Daniel Bach Gonzalez has left the board of directors of Cytoki Pharma ApS.
Cytoki Pharma ApS has published its annual report for 2023. Gross profit came to DKK -61,547,808, and the net result was DKK -64,519,466.
About Cytoki Pharma ApS
Cytoki Pharma ApS is a Danish company of the type Anpartsselskab based in Søborg, founded in 2019. The company is in liquidation. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CytoKi Pharma ApS. The management consists of Anders Hagstrøm. The company's owners include LUNDBECKFOND INVEST A/S, 15-Bio ApS and YSIOS Biofund III, F.C.R.E. The company has 3 employees (2026). In 2025, the company reported a gross profit of DKK -42,198,706 and a net result of DKK -43,800,007 compared with DKK -39,261,697 the year before. Equity in the 2025 report amounted to DKK 13,473,548.